Bevacizumab biosimilar - Beijing Mabworks Biotech

Drug Profile

Bevacizumab biosimilar - Beijing Mabworks Biotech

Alternative Names: MIL 60

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Mabworks Biotech
  • Developer Beijing Mabworks Biotech; Chinese PLA General Hospital
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 15 Aug 2017 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease, Recurrent, Combination therapy) in China (IV) (NCT03196986)
  • 25 Jun 2017 Beijing Mabworks Biotech plans a phase III trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in China (NCT03196986)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top